Baird’s Pacira BioSciences PCRX Stock Holding History

Baird’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	$16.7M	Buy	+187,689	New	+$19M	0.17%	164

Other funds holding PCRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baird's PCRX Position: Q1 2015 in Review

Baird opened a new position in Pacira BioSciences (PCRX) in Q1 2015: 187,689 shares worth $16.7M. The stake represents 0.17% of the portfolio and ranks #164 among its holdings.

205 funds tracked by Wall St. Rank hold PCRX as of Q1 2015.

Baird held 187,689 shares of Pacira BioSciences worth $16.7M as of Q1 2015.
Pacira BioSciences was a new Baird position in Q1 2015.
Pacira BioSciences made up 0.17% of Baird's portfolio in Q1 2015, its #164 holding.
205 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.